What is Protagonist Therapeutics's accounts payable?

Protagonist Therapeutics (PTGX) reported accounts payable of $3M in Q1 2026.

How has Protagonist Therapeutics's accounts payable changed year-over-year?

Protagonist Therapeutics's accounts payable increased by 142.8% year-over-year, from $1.24M to $3M.

Protagonist Therapeutics PTGX Accounts Payable

Accounts Payable at other companies

Spyre Therapeutics, Inc.SYRE

——

Immunovant, Inc.IMVT

——

ImmunityBio, Inc.IBRX

——

Other financials

Income statement

See full

Revenue$56.4M+99.0%

Operating income-$3.6M+81.1%

Net income$3.8M+132%

EPS (diluted)$0.05+126%

Balance sheet

See full

Cash & equivalents$193.7M+38.7%

Total debt$9.8M-13.9%

Total equity$655.5M-4.9%

Total assets$697.5M-6.0%

Cash flow

See full

Operating cash flow-$48.9M-139%

CapEx$215.0K-60.6%

Free cash flow-$49.2M-139%

Valuation

See full

Market cap$7.26B+127%

Enterprise value$7.07B+130%

P/S98×+82.6×

Profitability

See full

Operating margin-192.4%-205pp

Net margin-154.9%-182pp

FCF margin-12,264.3%-12,527pp

Returns & leverage

See full

Return on equity-17.1%-26.1pp

Debt / equity0×0.0×

Current ratio17.8×+0.5×

Where this comes from

Reported directly by Protagonist Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsPayableTrade.

The official record: Protagonist Therapeutics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Protagonist Therapeutics's accounts payable.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Protagonist Therapeutics's accounts payable?: Protagonist Therapeutics (PTGX) reported accounts payable of $3M in Q1 2026.
How has Protagonist Therapeutics's accounts payable changed year-over-year?: Protagonist Therapeutics's accounts payable increased by 142.8% year-over-year, from $1.24M to $3M.